Completed PHASE4 INTERVENTIONAL 4-arm NCT00118950

Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet

Effect of Metformin Versus Repaglinide Treatment on Glycemic Control and Non-Glycaemic Cardiovascular Risk Factors in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet

Sponsor: Steno Diabetes Center Copenhagen

Conditions Diabetes Mellitus, Type 2

Interventions Diet-only. Metformin Placebo-Metformin. Placebo-Repaglinide. Repaglinide

Updated 8 times since 2017 Last updated: Dec 5, 2008 Started: Mar 31, 2001 Completion: Mar 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Diabetes Mellitus, Type 2 and is currently completed. Steno Diabetes Center Copenhagen leads this study, which shows 8 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2019 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Jun 2019 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Steno Diabetes Center Copenhagen

Data source: Steno Diabetes Center Copenhagen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gentofte Municipality, Denmark